Skip to main content
Premium Trial:

Request an Annual Quote

Ventana Rejects Roche Acquisition Offer Again as Discussions Continue

NEW YORK (GenomeWeb News) – Ventana Medical Systems has urged its shareholders again to reject Roche’s extended offer to buy the firm for $75 per share.
The offer marks the fifth time that Roche has sought to get approval from Ventana’s shareholders to acquire the firm for $75 per share, or roughly $3 billion. Ventana’s stock closed yesterday at $86.07 on the Nasdaq.
Ventana issued a statement last night rejecting Roche’s latest offer, urging its stockholders “not to tender any of their shares to Roche at this inadequate price.” According to the Tucson, Ariz.-based company, less than .2 percent of its approximately 35 million outstanding shares have been tendered pursuant to the offer.
In an effort to get Roche to increase its offer, in November Ventana agreed to let Roche examine its books and gave the diversified Swiss healthcare giant access to non-public information that it believes would provide Roche greater insight into Ventana’s “business prospects and the inherent value in companion diagnostics.”
In the statement last night, Ventana President and CEO Christopher Gleeson said, “Our discussions with Roche under the confidentiality agreement are progressing, and we remain committed to providing superior value to our investors.”
Roche’s latest offer expires at 5:00 PM EST on March 14.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.